reviewed the role of immunotherapies in IC/BPS including anti-tumor necrosis factor-α (TNF- α), adalimumab, certolizumab pegol, anti-nerve growth factors agents, tanezumab, and fulranumab (34). This evidence concerns the gene TNF and Bartsocas-Papas syndrome 1.